Polypeptide vaccine against tumor-targeted drug resistance sites and design method thereof
A peptide vaccine and tumor targeting technology, applied in the field of peptide vaccines targeting tumor-targeted drug resistance sites and their design, can solve problems such as ambiguity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 2
[0161]Example 2, the construction of the second type of stable cell line at the specific mutation site of Ibrutinib that is resistant to BTK mutations:
[0162] Ibrutinib (ibrutinib) was purchased from Selleck Chemicals, human multiple myeloma cell line RPMI8226 ( CCL-155 TM ) was purchased from ATCC and cultured in RPMI 1640 medium plus 10% fetal bovine serum.
[0163] Purpose of the experiment: In order to verify that the T cells induced by the drug-resistant polypeptides of the present invention have killing activity, it is necessary to construct a set of stable cell lines containing the specific mutation sites of the present invention, capable of expressing and presenting these polypeptides
[0164] a. Construction of mutation site eukaryotic expression plasmid
[0165] The mini-gene capable of expressing all 5 vaccine polypeptides mutated in the present invention is obtained by artificial synthesis, which consists of the following parts: signal peptide part (lysosome-...
Embodiment 3
[0173] Example 3, the construction of the third type of stable transmutation cell line at the specific mutation site of some anti-androgen drugs such as abiraterone for AR drug resistance mutation;
[0174] Prostate cancer cell line PC-3 ( CRL-1435 TM ) was purchased from ATCC and cultured in F-12K medium plus 10% fetal bovine serum.
[0175] Purpose of the experiment: In order to verify that the T cells induced by the drug-resistant polypeptides of the present invention have killing activity, it is necessary to construct a set of stable cell lines containing the specific mutation sites of the present invention, capable of expressing and presenting these polypeptides
[0176] a. Construction of mutation site eukaryotic expression plasmid
[0177] The mini-gene capable of expressing all 4 vaccine polypeptides mutated in the present invention is obtained by artificial synthesis, which consists of the following parts: signal peptide part (lysosome-associated membrane glycopro...
Embodiment 4
[0185] Example 4, the construction of the fourth stable cell line for the specific mutation site of some fennel drugs targeting BRAF drug-resistant mutations;
[0186] Human melanoma cell line A378 was purchased from ATCC and cultured in DMEM medium plus 10% fetal bovine serum.
[0187] Purpose of the experiment: In order to verify that the T cells induced by the drug-resistant polypeptides of the present invention have killing activity, it is necessary to construct a set of stable cell lines containing the specific mutation sites of the present invention, capable of expressing and presenting these polypeptides
[0188] a. Construction of mutation site eukaryotic expression plasmid
[0189]The mini-gene capable of expressing all 7 vaccine polypeptides mutated in the present invention is obtained by artificial synthesis, which consists of the following parts: signal peptide part (lysosome-associated membrane glycoprotein 1, LAMP1), 7 mutated polypeptides and MHC class I traffi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com